SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals’ arm launches Sugammadex Injection

29 Jul 2026 Evaluate

Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark’s Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION Injection, 100 mg/mL of Merck Sharp & Dohme LLC.

According to IQVIA sales data for the 12-month period ending May 2026, the BRIDION Injection, 100 mg/mL market achieved annual sales of around $1.6 billion.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.


Glenmark Pharma. Share Price

2201.20 16.30 (0.75%)
29-Jul-2026 11:05 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1974.80
Dr. Reddys Labs. 1143.90
Cipla 1481.00
Lupin 2442.65
Zydus Lifesciences 1118.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: